Need Help? Chat Online or Toll Free: 1-800-891-0844
Cart (0)

Retatrutide

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Sign Up

Prescription Required

  • Related Products & Conditions

  • Product Details

    Description

    Retatrutide is an investigational triple-hormone receptor agonist targeting the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Developed by Eli Lilly and currently in clinical trials, Retatrutide is being evaluated for the treatment of obesity, type 2 diabetes, and associated metabolic disorders. By activating these three receptors, Retatrutide aims to promote weight loss, improve glycemic control, and enhance energy expenditure. Preliminary results from phase 2 trials suggest significant reductions in body weight and improvements in metabolic parameters compared to existing monotherapy or dual agonist approaches.

    Fact Table

    Formula

    C331H513N91O101S

    License

    Not yet approved (Phase 3 trials)

    Bioavailability

    High (subcutaneous; investigational data)

    Legal status

    Investigational

    Chemical Name

    Retatrutide (LY3437943)

    Elimination half-life

    ~6–7 days (estimated from Phase 2 data)

    Dosage (Strength)

    Weekly SC doses: 1–12 mg studied

    Pregnancy

    Not recommended (preclinical only)

    Brands

    None (not marketed)

    Protein binding

    Unknown (peptide-based; receptor mediated)

    PubChem CID

    166105968

    MedlinePlus

    Not listed

    ChEBI

    Not assigned

    ATC code

    None (not approved)

    DrugBank

    DB17920

    KEGG

    Not assigned

    Routes of administration

    Subcutaneous injection (weekly)

    Directions

    Retatrutide is administered via subcutaneous injection once weekly. Dosing regimens in clinical studies have varied, typically ranging from 1 mg to 12 mg per week, titrated to minimize gastrointestinal side effects and optimize therapeutic benefit. If approved, administration will require medical supervision, especially during initiation and dose escalation. Proper patient education on injection technique and adherence to scheduled follow-ups will be essential for safe and effective use.

    Ingredients

    As an investigational product, Retatrutide’s precise excipient formulation has not been publicly disclosed. The active pharmaceutical ingredient is:

    • Retatrutide (LY3437943), a synthetic peptide that acts as a GIP, GLP-1, and glucagon receptor agonist

    The formulation is designed for sustained subcutaneous delivery with extended receptor activity over the dosing interval.

    Contraindications

    Although formal contraindications will be finalized upon regulatory approval, based on class effects and clinical trial protocols, anticipated contraindications may include:

    • Personal or family history of medullary thyroid carcinoma (MTC)
    • Multiple endocrine neoplasia syndrome type 2 (MEN 2)
    • Hypersensitivity to any component of the formulation
    • History of pancreatitis (relative contraindication pending further data)

    Cautions

    Retatrutide may increase the risk of gastrointestinal disturbances, thyroid C-cell tumors (as seen in rodent studies with similar agents), and gallbladder-related disorders. Caution is advised in patients with a history of pancreatitis or severe gastrointestinal disease. Weight loss may affect the pharmacokinetics of other medications, especially those with narrow therapeutic indices. Long-term cardiovascular outcomes are under investigation, and prescribers should monitor metabolic parameters regularly during treatment.

    Side Effects

    Side effects observed in clinical trials include:

    • Nausea, vomiting, and diarrhea
    • Decreased appetite
    • Constipation
    • Injection site reactions
    • Hypoglycemia (particularly when used with insulin or sulfonylureas)
    • Potential for elevated pancreatic enzymes or gallbladder events
    • Rare: possible thyroid C-cell hyperplasia in preclinical models

    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14563

  • Product Reviews